A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.

Koichi HirataTakao Takeshima Noboru ImaiHisaka IgarashiMasako ShiosakaiMasanobu InageFumi SakuraiXiaoping NingMasami Nakai Nobuyuki Koga

Published in: Expert opinion on drug safety (2022)

Overall, AI-assisted, at-home self-injection of fremanezumab was found to be generally safe and well-tolerated. This injection strategy is considered clinically meaningful in view of improved utility of and adherence to the drug.

Keyphrases

open label
ultrasound guided
clinical trial
artificial intelligence
phase ii
squamous cell carcinoma
emergency department
study protocol
radiation therapy
machine learning
adipose tissue
insulin resistance
deep learning
rectal cancer
adverse drug
glycemic control